IGT-427

N/A

Report date: 2025/02/07 12:00:16

Base Information

Drug NameIGT-427
Drug Alias NameIGT-427
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsTEK receptor tyrosine kinase agonists
TargetsVascular endothelial growth factorTEK receptor tyrosine kinase
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIngenia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMosaic BiosciencesIngenia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A